Catalyst Pharmaceuticals, Inc. (CPRX) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Coral Gables, FL, アメリカ. 現CEOは Richard John Daly.
CPRX を有する IPO日 2006-11-08, 181 名の正社員, に上場 NASDAQ Capital Marke, 時価総額 $3.22B.
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company headquartered in Coral Gables, Florida, specializing in therapies for rare neuromuscular and neurological diseases. The company's primary product, Firdapse (amifampridine phosphate), is approved for treating Lambert-Eaton Myasthenic Syndrome (LEMS) in adults, while its pediatric formulation, Ruzurgi, addresses LEMS in children. Catalyst is advancing Firdapse through clinical development for additional indications including MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. The company maintains strategic partnerships with BioMarin Pharmaceutical Inc. and Endo Ventures Limited for product development and commercialization efforts.
